Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Michael A. Davies, MD, PhD

Professor and Chair
Department of Melanoma Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Michael A. Davies, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: ABM Therapeutics; Apexigen; Array; Bristol Myers Squibb; Eisai; Iovance; Novartis; Pfizer; Roche/Genentech; Vaccinex
Research funding from: ABM Therapeutics; LEAD Pharm
Contracted researcher for: Pfizer

Charlotte E. Ariyan, MD, PhD

Associate Attending and Oncology
Surgeon, Melanoma and Sarcoma
Memorial Sloan Kettering Cancer Center
New York, New York

Disclosures

Charlotte E. Ariyan, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Iovance; Merck
Owns stock (publicly traded) in: Pfizer

Kelly Nelson, MD

Professor
Department of Dermatology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Kelly Nelson, MD, has no relevant financial relationships.

Editors

Deborah Middleton, MS

Senior Medical Education Director, Medscape, LLC

Disclosures

Deborah Middleton, MS, has no relevant financial relationships.

Yoji Yamaguchi, MA, ELS

Scientific Content Manager, Medscape, LLC

Disclosures

Yoji Yamaguchi, MA, ELS, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC

A New Era of Progress for Melanoma: Leveling-Up With Immunotherapy

Authors: Michael A. Davies, MD, PhD; Charlotte E. Ariyan, MD, PhD; Kelly Nelson, MD
CME / ABIM MOC Released: 11/29/2022
Valid for credit through: 11/29/2023

Start Activity

Credits Available

Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 0.50 ABIM MOC points

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, including surgical oncologists, dermatologists, pathologists, surgeons, and other members of the multidisciplinary care team.

The goal of this activity is for learners to be better able to recognize treatment strategies involving immunotherapy being evaluated across the spectrum of melanoma and how they impact the multidisciplinary management of these patients.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Key clinical trial data evaluating immunotherapy-containing regimens for the management of patients with melanoma
Have greater competence related to
- Individualizing care for patients receiving immunotherapy-containing regimens for the management of melanoma
Demonstrate greater confidence in their ability to
- Coordinate with the multidisciplinary team in order to optimize care for patients with melanoma

Disclosures

Faculty

Michael A. Davies, MD, PhD

Professor and Chair
Department of Melanoma Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Michael A. Davies, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: ABM Therapeutics; Apexigen; Array; Bristol Myers Squibb; Eisai; Iovance; Novartis; Pfizer; Roche/Genentech; Vaccinex
Research funding from: ABM Therapeutics; LEAD Pharm
Contracted researcher for: Pfizer

Charlotte E. Ariyan, MD, PhD

Associate Attending and Oncology
Surgeon, Melanoma and Sarcoma
Memorial Sloan Kettering Cancer Center
New York, New York

Disclosures

Charlotte E. Ariyan, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Iovance; Merck
Owns stock (publicly traded) in: Pfizer

Kelly Nelson, MD

Professor
Department of Dermatology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Kelly Nelson, MD, has no relevant financial relationships.

Editors

Deborah Middleton, MS

Senior Medical Education Director, Medscape, LLC

Disclosures

Deborah Middleton, MS, has no relevant financial relationships.

Yoji Yamaguchi, MA, ELS

Scientific Content Manager, Medscape, LLC

Disclosures

Yoji Yamaguchi, MA, ELS, has no relevant financial relationships.

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

Developed through a partnership between Medscape and Society for Melanoma Research.

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

A New Era of Progress for Melanoma: Leveling-Up With Immunotherapy

Authors: Michael A. Davies, MD, PhD; Charlotte E. Ariyan, MD, PhD; Kelly Nelson, MDFaculty and Disclosures

CME / ABIM MOC Released: 11/29/2022

Valid for credit through: 11/29/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Adjuvant and Neoadjuvant Melanoma Strategies

What are your strategies for using neoadjuvant and adjuvant immunotherapy for patients with melanoma? Hear our experts discuss the current landscape.
Michael A. Davies, MD, PhD; Charlotte E. Ariyan, MD, PhD

Metastatic Melanoma: Long-Term Outcomes and Future Prospects

Drs Davies and Ariyan review current and emerging immunotherapy options for managing stage IV melanoma.
Michael A. Davies, MD, PhD; Charlotte E. Ariyan, MD, PhD

Practical Considerations for the Real World

Listen to valuable insights from the clinic on the multidisciplinary management of melanoma.
Michael A. Davies, MD, PhD; Kelly Nelson, MD

Learning Feedback Questions

What did you learn from this activity? Please proceed to a brief survey.

Page 1 of 6

CME / ABIM MOC Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Michael A. Davies, MD, PhD

Charlotte E. Ariyan, MD, PhD

Kelly Nelson, MD

Editors

Deborah Middleton, MS

Yoji Yamaguchi, MA, ELS

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC

A New Era of Progress for Melanoma: Leveling-Up With Immunotherapy

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Michael A. Davies, MD, PhD

Charlotte E. Ariyan, MD, PhD

Kelly Nelson, MD

Editors

Deborah Middleton, MS

Yoji Yamaguchi, MA, ELS

Compliance Reviewer

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

A New Era of Progress for Melanoma: Leveling-Up With Immunotherapy

Contents of This CME Activity

Adjuvant and Neoadjuvant Melanoma Strategies

Metastatic Melanoma: Long-Term Outcomes and Future Prospects

Practical Considerations for the Real World

Learning Feedback Questions